LG, Mochida announce development and licensing agreement for biosimilar

Published: 2012-11-09 06:56:00

Updated: 2012-11-09 06:56:00

LG Life Sciences (LGLS) announced Wednesday that it has granted Japan based Mochida Pharmaceutical Co. an exclusive license to develop, register and market a biosimilar drug developed by LGLS in Korea and Japan.

The terms of the agreement include an upfront payment and and additional milestone...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK